Success Metrics

Clinical Success Rate
69.2%

Based on 9 completed trials

Completion Rate
69%(9/13)
Active Trials
0(0%)
Results Posted
133%(12 trials)
Terminated
4(31%)

Phase Distribution

Ph phase_4
2
15%
Ph phase_1
1
8%
Ph phase_3
2
15%
Ph phase_2
8
62%

Phase Distribution

1

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(4)

Detailed Status

Completed9
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
69.2%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 28 (61.5%)
Phase 32 (15.4%)
Phase 42 (15.4%)

Trials by Status

terminated431%
completed969%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_4

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
terminatedphase_2

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

NCT02749227
completedphase_2

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

NCT01563354
completedphase_1

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

NCT01364415
completedphase_2

Pasireotide LAR in Severe Polycystic Liver Disease

NCT01670110
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01794793Phase 4

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Completed
NCT02749227Phase 2

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

Terminated
NCT01563354Phase 2

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Completed
NCT01364415Phase 1

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Completed
NCT01670110Phase 2

Pasireotide LAR in Severe Polycystic Liver Disease

Completed
NCT02354508Phase 3

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Completed
NCT01673646Phase 2

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Completed
NCT02060383Phase 4

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Completed
NCT01283542Phase 2

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Completed
NCT01374906Phase 3

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Completed
NCT00929669Phase 2

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Terminated
NCT01374451Phase 2

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Terminated
NCT00958841Phase 2

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Terminated

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13